Crossmark

Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada

Crossref DOI link: https://doi.org/10.1016/j.medcli.2021.01.006

Published Print: 2021-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Aomar-Millán, Ismael Francisco

Salvatierra, Juan

Torres-Parejo, Úrsula

Nuñez-Nuñez, María

Hernández-Quero, José

Anguita-Santos, Francisco
Funding

Funding for this research was provided by:

Secretaría de Estado de Investigacion, Desarrollo e Innovacion

Junta de Andalucía
License Information

Text and Data Mining valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01

stm-asf valid from 2021-06-01
More Information

This article is maintained by: Elsevier

Article Title: Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada

Journal Title: Medicina Clínica

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.medcli.2021.01.006

Content Type: simple-article

Copyright: © 2021 Elsevier España, S.L.U. All rights reserved.

Document is current

Any future updates will be listed below